 |
2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate |
|---|---|
| Trade Name | |
| Orphan Indication | Acute myeloid leukaemia |
| EU Market Approval | EU |
| EU Designation Date | 2016-04-28 00:00:00 |
| Sponsor | Celgene Europe Limited |
